Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 : A Randomized Trial.

ABSTRACT:

Background

No effective oral therapy exists for early coronavirus disease 2019 (COVID-19).

Objective

To investigate whether hydroxychloroquine could reduce COVID-19 severity in adult outpatients.

Design

Randomized, double-blind, placebo-controlled trial conducted from 22 March through 20 May 2020. (ClinicalTrials.gov: NCT04308668).

Setting

Internet-based trial across the United States and Canada (40 states and 3 provinces).

Participants

Symptomatic, nonhospitalized adults with laboratory-confirmed COVID-19 or probable COVID-19 and high-risk exposure within 4 days of symptom onset.

Intervention

Oral hydroxychloroquine (800 mg once, followed by 600 mg in 6 to 8 hours, then 600 mg daily for 4 more days) or masked placebo.

Measurements

Symptoms

SUBMITTER: Skipper CP 

PROVIDER: S-EPMC7384270 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature